Showing results (91-100 of 145) with videos related to

Sort By:
Pageof 15
Oncology|October 2, 2008
A treatment selection protocol for recurrent ovarian cancer patients: the role of FDG-PET/CT and staging laparoscopyA Fagotti, F Fanfani, C Rossitto, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 20, 2015
How often parametrial involvement leads to post-operative adjuvant treatment in locally advanced cervical cancer after neoadjuvant chemotherapy and type C radical hysterectomy?F Martinelli, G Bogani, A Ditto, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|July 6, 2016
Is aortic lymphadenectomy indicated in locally advanced cervical cancer after neoadjuvant chemotherapy followed by radical surgery? A retrospective study on 261 womenF Martinelli, M Signorelli, G Bogani, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 12, 2014
Class II versus Class III radical hysterectomy in early cervical cancer: an observational study in a tertiary centerA Ditto, F Martinelli, S Ramondino, et al.
Techniques in Coloproctology|March 17, 2015
Prospective multicenter observational trial on the safety and efficacy of LEVORAG® Emulgel in the treatment of acute and chronic anal fissureR Digennaro, G Pecorella, S La Manna, et al.
Gynecologic Oncology|July 6, 2010
Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9)G Mangili, G Scarfone, A Gadducci, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2009
Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) GroupD Lorusso, G Ferrandina, S Pignata, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 2, 2007
Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II studyG Ferrandina, M Ludovisi, R De Vincenzo, et al.
Cancer Treatment Reviews|October 11, 2021
Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitorsM Bartoletti, L Musacchio, G Giannone, et al.
Scandinavian Journal of Gastroenterology|March 1, 2003
Increased farnesyltransferase activity in human colorectal cancer: relationship with clinicopathological features and K-ras mutationM G Caruso, M Notarnicola, M Bifulco, et al.
Pageof 15